AQST News and Press, Aquestive Therapeutics Inc. From 11/01/22

Aquestive Therapeutics press release ( NASDAQ: AQST ): Q3 GAAP EPS of -$0.23 beats by $0.07 . Revenue of $11.46M (-13.7% Y/Y) beats by $0.42M . For further details see: Aquestive Therapeutics GAAP EPS of -$0.23 beats by $0.07, revenue of $11.46M beats by ...

Reported positive data from EPIPHAST II trial comparing AQST-109 (epinephrine sublingual film) to EpiPen® 0.3mg (single dose) and AQST-109 to epi 0.3mg IM injection (repeat dose) Scheduled End-of-Phase 2 (EoP2) meeting with FDA on AQST-109 for fourth quarter 2022 Generated ...

We’re quickly approaching the end of the first month in Q4. With that has come ten months of wild trading activity and plenty of volatility. Heading into November, there are plenty of new catalysts to account for, including next week’s FOMC meeting. But before November begins,...

Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) announced Thursday a deal to license its anti-seizure therapy Sympazan (clobazam) oral film to Otter Pharmaceuticals, LLC, a unit of Assertio Holdings, Inc. ( NASDAQ: ASRT ). Per the terms, Aquestive ( AQST ) is set...

WARREN, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today a transaction to license Sympazan® ...

Trailing 12 Month Revenues of Sympazan Were $9.5 Million Assertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company ...

WARREN, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today that the United States District Court fo...

WARREN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, today announced that it will report results for third qu...

Aquestive Therapeutics ( NASDAQ: AQST ) said on Tuesday it had received positive feedback from the U.S. Food and Drug Administration for its initial End-of-Phase 2 (EoP2) meeting request to discuss Chemistry, Manufacturing, and Controls for its AQST-109 epinephrine su...

FDA’s End-of-Phase 2 written response provides positive feedback related to Chemistry, Manufacturing, and Controls (CMC) to support future NDA filing Supports approach to characterizing Aquestive’s proprietary novel prodrug form of epinephrine API Confirms ...